Shares of Janux Therapeutics (JANX) were rallying Tuesday after the biopharmaceutical company reported late Monday positive interim clinical data for its JANX007 clinical program in prostate cancer patients.
The company said high prostate-specific antigen response rates and deep PSA declines were observed in all doses in the phase 1a clinical trial, which also showed that JANX007 has a well-tolerated safety profile.
Janux said that based on these results, two once-weekly step dose regimens have been identified for phase 1b expansion trials.
Price: 61.56, Change: +21.38, Percent Change: +53.21
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.